Trial
NCT05073458
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Warm Autoimmune Hemolytic Anemia (wAIHA)
Intervention
parsaclisinib
Why stopped
A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-03